文献速递骨肌PETCT

18F-NaF SUVmax提示强直性脊柱炎患者对肿瘤坏死因子-α阻断剂的治疗反应,而定量药代动力学分析无此提示作用

Prediction of Response to Tumor Necrosis Value-α Blocker Is Suggested by 18F-NaF SUVmax But Not by Quantitative Pharmacokinetic Analysis in Patients With Ankylosing Spondylitis.
PubMed 文献 · AJR Am J Roentgenol · 2020-04-14

纳入27例接受肿瘤坏死因子-α阻断剂治疗的强直性脊柱炎患者,行骨盆动态PET及全身PET/CT,计算骶髂关节动力学参数及骶髂关节、脊柱SUVmax。脊柱SUVmax与BASDAI评分正相关(r=0.38,p=0.048),且与BASDAI 50反应预测相关(OR 14.69,95%CI 0.79-27.27,p=0.027),作者认为脊柱SUVmax是预测治疗反应的可靠无创生物标志物,但需更大队列验证。

要点

  • 脊柱18F-NaF SUVmax在反应者中显著高于无反应者。
  • 脊柱SUVmax与BASDAI评分呈正相关(r=0.38,p=0.048)。
  • 脊柱SUVmax与BASDAI 50反应预测相关(OR 14.69,95%CI 0.79-27.27,p=0.027)。

关键影像表现/征象

  • 反应者与无反应者在18F-NaF PET/CT时的BASDAI评分有显著差异。
  • 反应者的脊柱18F-NaF摄取显著高于无反应者。
  • 18F-NaF PET/CT可显示轴骨成骨性病变。

诊断标准与关键数值

  • 临床反应定义为基线18F-NaF PET/CT后2年内BASDAI评分改善≥50%(BASDAI 50)。
  • BASDAI评分(OR 35.32,95%CI 2.09-57.84,p=0.014)与BASDAI 50反应预测显著相关。
  • 脊柱SUVmax(OR 14.69,95%CI 0.79-27.27,p=0.027)与BASDAI 50反应预测显著相关。
  • 仅脊柱SUVmax与PET/CT时BASDAI评分呈显著正相关(r=0.38,p=0.048)。

临床应用与阅片要点

  • 作者认为全身18F-NaF PET/CT的脊柱SUVmax可用于预测强直性脊柱炎患者对肿瘤坏死因子-α阻断剂的治疗反应。
  • 作者指出18F-NaF PET/CT可显示轴骨成骨性病变,可作为接受抗肿瘤坏死因子-α药物治疗的强直性脊柱炎患者的监测工具。
  • 作者认为脊柱SUVmax预测治疗反应的表现优于定量药代动力学参数。

局限性

  • 作者指出这些结果需要在更大队列中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE. We aimed to evaluate the pharmacokinetics and maximum standardized uptake value (SUVmax) of 18F-NaF PET/CT for assessment of disease activity and prediction of response in patients with ankylosing spondylitis (AS). MATERIALS AND METHODS. Twenty-seven patients (age, interquartile range, 30.25-49.75 years) with AS who were receiving a tumor necrosis factor-α (TNF-α) blocker were included. All patients underwent dynamic PET of the pelvis followed by whole-body PET/CT. Quantitative analysis of kinetic data of the sacroiliac joints (SIJs) was performed, and the SUVmax of the SIJs and SUVmax of the spine were calculated. Clinical indexes related to AS disease activity (serum C-reactive protein level, Bath ankylosing spondylitis disease activity index [ BASDAI], and Bath ankylosing spondylitis functional index) were evaluated. Clinical response was defined as an improvement from the initial BASDAI score of 50% or more (BASDAI 50) within 2 years after baseline 18F-NaF PET/CT. RESULTS. The BASDAI score at 18F-NaF PET/CT was significantly different between the responders and nonresponders: 18F-NaF uptake at the spine was significantly higher in the responders than in the nonresponders. Only SUVmax of the spine had a significant positive correlation with BASDAI score at PET/CT (r = 0.38, p = 0.048). The BASDAI score at PET/CT (odds ratio [OR], 35.32; 95% CI, 2.09-57.84; p = 0.014) and SUVmax of the spine (OR, 14.69; 95% CI, 0.79-27.27; p = 0.027) were significantly associated with BASDAI 50 response prediction. CONCLUSION. The results of our study suggest that the SUVmax of the spine on whole-body 18F-NaF PET/CT is a reliable and noninvasive biomarker for predicting therapeutic response to TNF-α blocker and shows better performance for predicting response than quantitative pharmacokinetic parameters. Fluorine-18-labeled NaF PET/CT showed axial bone lesions with bone formation and can be used as a monitoring tool in patients with AS receiving anti-TNF-α drugs. However, these results need to be validated in a larger cohort.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Kim K, Son SM, Goh TS, et al. Prediction of Response to Tumor Necrosis Value-α Blocker Is Suggested by 18F-NaF SUVmax But Not by Quantitative Pharmacokinetic Analysis in Patients With Ankylosing Spondylitis. AJR Am J Roentgenol. 2020. PMID: 32286869. doi:10.2214/AJR.19.22352

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。